Clinically, we found that loss of STK16 or pharmacological STK16 inhibitor (STK16-IN-1) demonstrated promising effectiveness in inhibiting CRC proliferation by impairing c-MYC oncogene signaling (Fig. 7M). The gene discussed is STK16; the disease is colorectal carcinoma.